R289
2 abstracts
Abstract
Phase 1b trial of IRAK 1/4 inhibition for low-risk myelodysplastic syndrome refractory/resistant to prior therapies.Org: Rigel Pharmaceuticals, Inc.,
Abstract
Phase 1b clinical study of IRAK 1/4 inhibition for low-risk myelodysplastic syndromes refractory/resistant to prior therapies.Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, Rigel Pharmaceuticals, Inc., South San Francisco, CA,